Page 90 - GTM-2-4

Global Translational Medicine Prognosis of relapse in squamous cell lung cancer

Funding https://doi.org/10.1016/j.jss.2010.04.039

The work was carried out with financial support from 4. Kerr KM, Nicolson MC, 2013, Prognostic factors in resected
the Ministry of Health of the Republic of Belarus (grant lung carcinomas. EJC Suppl, 11: 137–149.
number: 2.17/20220385). https://doi.org/10.1016/j.ejcsup.2013.07.023
Conflict of interest 5. Remon J, Soria JC, Peters S, 2021, Early and locally advanced
non-small-cell lung cancer: An update of the ESMO clinical
All authors declare no conflict of interest. practice guidelines focusing on diagnosis, staging, systemic
and local therapy. Ann Oncol, 32: 1637–1642.
Author contributions https://doi.org/10.1016/j.annonc.2021.08.1994
Conceptualization: Anatoli D. Tahanovich, Violetta I. 6. Tahanovich AD, Kauhanka NN, Prohorova VI, et al., 2022,
Prokhorova Determination of the risk of tumor progression in patients
Formal analysis: Anatoli D. Tahanovich, Mikalai M. with early stages of adenocarcinoma and squamous cell
Kauhanka lung carcinoma based on laboratory parameters. Biochem
Investigation: Mikalai M. Kauhanka, Zhanna A. Moscow Suppl Ser B, 16: 154–163.
Rutkovskaya, Ekaterina A. Khotko, Oxana V. Gotko https://doi.org/10.1134/S1990750822020081
Methodology: Anatoli D. Tahanovich, Mikalai M. Kauhanka
Writing – original draft: Anatoli D. Tahanovich, Mikalai M. 7. Kuribayashi K, Funaguchi N, Nakano T, 2016, Chemotherapy
for advanced non-small cell lung cancer with a focus on
Kauhanka squamous cell carcinoma. J Cancer Res Ther, 12: 528–534.
Writing – review and editing: Anatoli D. Tahanovich,
Mikalai M. Kauhanka, Violetta I. Prokhorova https://doi.org/10.4103/0973-1482.174185
8. Suminami Y, Nawata S, Kato H, 1998, Biological role of SCC
Ethics approval and consent to participate antigen. Tumour Biol, 19: 488–493.
All patients gave written voluntary consent to participate https://doi.org/10.1159/000030042
in the study. The study was approved by the decision of 9. Zhang W, Wang H, Sun M, et al., 2020, CXCL5/CXCR2
the Biomedical Ethics Committee of the Belarusian State axis in tumor microenvironment as potential diagnostic
Medical University (Committee meeting No. 2, dated biomarker and therapeutic target. Cancer Commun (Lond),
10/04/2021). 40: 69–80.

Consent for publication https://doi.org/10.1002/cac2.12010
10. Chen C, Zhao S, Karnad A, et al., 2018, The biology and role
All patients gave written voluntary consent for publishing of CD44 in cancer progression: Therapeutic implications.
their data in this paper. J Hematol Oncol, 11: 64.
Availability of data https://doi.org/10.1186/s13045-018-0605-5

Data used in this work are available from the corresponding 11. Parikh R, Mathai A, Parikh S, et al., 2008, Understanding
author on reasonable request. and using sensitivity, specificity and predictive values.
Indian J Ophthalmol, 56: 45–50.
References https://doi.org/10.4103/0301-4738.37595
1. Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer 12. Lagiou P, Trichopoulos D, 2011, Inflammatory biomarkers
statistics 2020: GLOBOCAN estimates of incidence and and risk of lung cancer. J Natl Cancer Inst, 103: 1073–1075.
mortality worldwide for 36 cancers in 185 countries. CA
Cancer J Clin, 71: 209–249. https://doi.org/10.1093/jnci/djr220
https://doi.org/10.3322/caac.21660 13. Spaks A, 2017, Role of CXC group chemokines in lung cancer
development and progression. J Thorac Dis, 9: S164–S171.
2. Araghi M, Mannani R, Maleki AH, et al., 2023, Recent
advances in non-small cell lung cancer targeted therapy; an https://doi.org/10.21037/jtd.2017.03.61
update review. Cancer Cell Int, 23: 162. 14. Zhao S, He JL, Qiu ZX, et al., 2014, Prognostic value of CD44
variant exon 6 expression in non-small cell lung cancer:
https://doi.org/10.1186/s12935-023-02990-y
A meta-analysis. Asian Pac J Cancer Prev, 15: 6761–6766.
3. Wang CY, Huang MS, Huang MH, et al., 2010, Persistently
high serum carcinoembryonic antigen levels after surgery https://doi.org/10.7314/apjcp.2014.15.16.6761
indicate poor prognosis in patients with stage I non-small- 15. Luo Z, Wu RR, Lu L, et al., 2014, Prognostic value of CD44
cell lung cancer. J Surg Res, 163: e45–e50. expression in non-small cell lung cancer: A systematic

Volume 2 Issue 4 (2023) 11 https://doi.org/10.36922/gtm.2209